Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study

CompletedOBSERVATIONAL
Enrollment

351

Participants

Timeline

Start Date

August 19, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions
Metastatic Endometrial Cancer
Trial Locations (24)

13009

Institut Paoli Calmettes, Marseille

14000

Centre François Baclesse, Caen

21079

CHU de DIJON, Dijon

22190

Centre CARIO-HPCA, Plérin

25000

CHU Jean Minjoz, Besançon

26953

Centre Hospitalier de Valence, Valence

29107

CHI de Cornouaille, Quimper

31059

Oncopole Claudius Regaud - IUCT Oncopole, Toulouse

33000

Clinique TIVOLI, Bordeaux

34298

ICM Val d'Aurelle, Montpellier

35000

Centre Eugène Marquis, Rennes

37044

CHU Tours - Hôpital Bretonneau, Tours

42100

CHU Saint-Etienne - Hôpital Bellevue, Saint-Etienne

49055

ICO Paul Papin, Angers

51430

ICONE, Bezannes

63011

Centre Jean Perrin, Clermont-Ferrand

67033

ICANS, Strasbourg

69008

Centre Léon Bérard, Lyon

71100

Centre Hospitalier William Morey, Chalon-sur-Saône

75015

Hôpital Européen George Pompidou, Paris

77980

Centre Georges François Leclerc, Dijon

84918

Sainte Catherine - Institut du Cancer Avignon, Avignon

86021

CHU de Poitiers - Hôpital de la Milétrie, Poitiers

92210

Institut Curie, Saint-Cloud

All Listed Sponsors
collaborator

Institut Curie

OTHER

lead

ARCAGY/ GINECO GROUP

OTHER

NCT06599463 - Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study | Biotech Hunter | Biotech Hunter